Genome wide DNA copy number analysis of serous type ovarian carcinomas identifies genetic markers predictive of clinical outcome.
about
Tensor GSVD of patient- and platform-matched tumor and normal DNA copy-number profiles uncovers chromosome arm-wide patterns of tumor-exclusive platform-consistent alterations encoding for cell transformation and predicting ovarian cancer survivalA systematic comparison of copy number alterations in four types of female cancerDiscovery analysis of TCGA data reveals association between germline genotype and survival in ovarian cancer patientsIdentification of mutated core cancer modules by integrating somatic mutation, copy number variation, and gene expression data.Somatic mutations favorable to patient survival are predominant in ovarian carcinomasCyclin E1 deregulation occurs early in secretory cell transformation to promote formation of fallopian tube-derived high-grade serous ovarian cancers.Identification of recurrent focal copy number variations and their putative targeted driver genes in ovarian cancerOvarian cancer: in search of better marker systems based on DNA repair defectsFGF18 as a prognostic and therapeutic biomarker in ovarian cancer.Ovarian cancer: genomic analysis.Loss of LKB1 and PTEN tumor suppressor genes in the ovarian surface epithelium induces papillary serous ovarian cancer.Genome-wide DNA copy number analysis in clonally expanded human ovarian cancer cells with distinct invasive/migratory capacities.Molecular diagnosis and molecular profiling to detect treatment-resistant ovarian cancer.Promoter methylation of the SALL2 tumor suppressor gene in ovarian cancers.Deletion at 6q24.2-26 predicts longer survival of high-grade serous epithelial ovarian cancer patients.Integrated genomic analysis of clear cell ovarian cancers identified PRKCI as a potential therapeutic target.
P2860
Q21090556-C96F5D12-A67A-4936-99DD-96148EA32C0EQ28394747-BAAB3AEF-6526-45A0-B026-C6C90510A869Q30612061-0DC56D54-778C-409E-A156-6513E82588A4Q30763468-DAB4C45D-28E5-4ADC-A6DF-F38CD9F8A089Q34497796-E5E79F49-346B-41C6-8766-A0D2CE403CBEQ35897417-0D518D09-F0BF-41A5-9805-44AC5CBEA395Q36031493-8D1F842C-E23E-4DF9-AF15-260977CC195BQ36589947-C36A5DBE-DD9E-4F3B-8CBF-F81270DC8F45Q37200903-A8C16968-BCCE-4BA9-BC71-62A8D86FA15EQ37332480-D8987D57-E2FD-433C-9E3A-4EF0E7AC28B3Q37616060-8B8535CA-53C6-49B1-AF62-4C3369AE8706Q37716509-13E3B89E-07DA-4E24-A740-32012FED798BQ38832323-075481AE-4C7D-4A22-9B76-7AE198FBE32FQ39219310-E4BE8453-FB6F-42AB-B28C-21D574ED6062Q41135676-587E8556-25DD-4FA0-A06E-E90C780A80BEQ47123431-7D6E41DD-FCF7-4525-BA66-2B2E4A5CBAFE
P2860
Genome wide DNA copy number analysis of serous type ovarian carcinomas identifies genetic markers predictive of clinical outcome.
description
2012 nî lūn-bûn
@nan
2012 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Genome wide DNA copy number an ...... redictive of clinical outcome.
@ast
Genome wide DNA copy number an ...... redictive of clinical outcome.
@en
Genome wide DNA copy number an ...... redictive of clinical outcome.
@nl
type
label
Genome wide DNA copy number an ...... redictive of clinical outcome.
@ast
Genome wide DNA copy number an ...... redictive of clinical outcome.
@en
Genome wide DNA copy number an ...... redictive of clinical outcome.
@nl
prefLabel
Genome wide DNA copy number an ...... redictive of clinical outcome.
@ast
Genome wide DNA copy number an ...... redictive of clinical outcome.
@en
Genome wide DNA copy number an ...... redictive of clinical outcome.
@nl
P2093
P2860
P1433
P1476
Genome wide DNA copy number an ...... redictive of clinical outcome.
@en
P2093
Beth Y Karlan
Bo R Rueda
David A Engler
David M Gershenson
Gayatry Mohapatra
Jenny Gross
Joe W Gray
Michael J Birrer
Michael T Deavers
P2860
P304
P356
10.1371/JOURNAL.PONE.0030996
P407
P577
2012-02-15T00:00:00Z